Iolyx Inks Dry Eye Deal With Théa, Secures Series B Funds
Iolyx Therapeutics has signed a global development and commercialization deal with Laboratoires Théa for ILyx-002 in ocular surface disease,...
TScan’s Alloha™ Heme Trial Shows Promising Phase 1 Results
TScan Therapeutics reported updated Phase 1 results from the ALLOHA trial of TSC-101, a TCR-engineered T cell therapy given...
Leqembi Data Confirms Effect on Alzheimer’s Protofibrils
Eisai and Biogen reported new cerebrospinal fluid data at CTAD showing that lecanemab’s binding to amyloid beta protofibrils can...
Cosmos CEO’s Surging 3.4M Share Purchase Signals Faith
Cosmos Health’s chief executive, Greg Siokas, has increased his personal stake in the company, acquiring 301,101 shares across five...
Addex Therapeutics Q3 2025 Financials & Corporate Update
Addex Therapeutics reported third-quarter 2025 results and a focused R&D update, highlighting continued progress of its GABAB positive allosteric...
DOGP In Strategic Move To Nearly Double Dog Token Holdings
Dogecoin Cash, Inc. has agreed, via its MEMECOINS, Inc. subsidiary, to acquire 4 billion DOG tokens from Tipestry, lifting...
Parkinson’s Drug Crexont® Shows Promising Phase 4 Results
Amneal reported positive interim results from its ongoing Phase 4 ELEVATE-PD switch study, showing that CREXONT (carbidopa/levodopa extended-release) improved...
Laigo Bio Secures €11.5M for Protein Degradation Platform
Laigo Bio has raised €11.5 million in seed financing and appointed Matthew Baker as CEO to accelerate its SureTAC...
Positive Phase 3 VALIANT Results for Empaveli Published
Apellis has secured a decisive evidence win for Empaveli (pegcetacoplan) in rare renal disease: the New England Journal of...
Amicus Therapeutics Q3 2025 Financial Results Announced
Amicus Therapeutics reported third-quarter 2025 revenue of $169.1 million, up 17% at constant exchange rates, and delivered GAAP net...